165 related articles for article (PubMed ID: 23187773)
41. Zoledronic acid for all patients with newly diagnosed multiple myeloma?
Terpos E; Dimopoulos MA
Lancet Oncol; 2011 Aug; 12(8):711-2. PubMed ID: 21771569
[No Abstract] [Full Text] [Related]
42. An anti-B cell maturation antigen bispecific antibody for multiple myeloma.
Ramadoss NS; Schulman AD; Choi SH; Rodgers DT; Kazane SA; Kim CH; Lawson BR; Young TS
J Am Chem Soc; 2015 Apr; 137(16):5288-91. PubMed ID: 25826669
[TBL] [Abstract][Full Text] [Related]
43. A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma.
Musto P; Petrucci MT; Bringhen S; Guglielmelli T; Caravita T; Bongarzoni V; Andriani A; D'Arena G; Balleari E; Pietrantuono G; Boccadoro M; Palumbo A;
Cancer; 2008 Oct; 113(7):1588-95. PubMed ID: 18683218
[TBL] [Abstract][Full Text] [Related]
44. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
45. Complete clinical and biological response to zoledronic acid in castrate-resistant prostate cancer metastatic to bone.
Pouessel D; Culine S
Anticancer Drugs; 2012 Jan; 23(1):141-2. PubMed ID: 21934600
[TBL] [Abstract][Full Text] [Related]
46. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
[TBL] [Abstract][Full Text] [Related]
47. Clinical utility of biochemical markers of bone metabolism for improving the management of patients with advanced multiple myeloma.
Lipton A; Cook RJ; Coleman RE; Smith MR; Major P; Terpos E; Berenson JR
Clin Lymphoma Myeloma; 2007 Mar; 7(5):346-53. PubMed ID: 17562244
[TBL] [Abstract][Full Text] [Related]
48. Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C; Laubach JP; Anderson KC; Richardson PG
Br J Haematol; 2018 May; 181(4):433-446. PubMed ID: 29748955
[TBL] [Abstract][Full Text] [Related]
49. Perspective study on pamidronate in stage I multiple myeloma.
Caparrotti G; Catalano L; Feo C; Vallone R; Pagnini D; Rotoli B
Hematol J; 2003; 4(6):459-60. PubMed ID: 14671624
[No Abstract] [Full Text] [Related]
50. Proteasome inhibitors: introduction.
Heuck CJ; Shaughnessy JD
Semin Hematol; 2012 Jul; 49(3):193-5. PubMed ID: 22726541
[No Abstract] [Full Text] [Related]
51. New Drugs in Multiple Myeloma.
Kunacheewa C; Orlowski RZ
Annu Rev Med; 2019 Jan; 70():521-547. PubMed ID: 30691369
[TBL] [Abstract][Full Text] [Related]
52. Anti-BCMA antibodies in the future management of multiple myeloma.
Gavriatopoulou M; Ntanasis-Stathopoulos I; Dimopoulos MA; Terpos E
Expert Rev Anticancer Ther; 2019 Apr; 19(4):319-326. PubMed ID: 30810049
[TBL] [Abstract][Full Text] [Related]
53. Immunopathogenesis and immunotherapy of multiple myeloma.
Tamura H
Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
[TBL] [Abstract][Full Text] [Related]
54. Hemorrhagic bullous colitis in a patient with multiple myeloma.
Cho SH; Kim SW; Kim WC; Chul-Hyun L; Go BS
Endoscopy; 2013; 45 Suppl 2 UCTN():E157-8. PubMed ID: 23716110
[No Abstract] [Full Text] [Related]
55. Fragile bones in a young male.
Hasan U; Rasool H
South Med J; 2006 Oct; 99(10):1143-4. PubMed ID: 17100041
[No Abstract] [Full Text] [Related]
56. B-cell maturation antigen directed monoclonal antibody therapies for multiple myeloma.
Eckhert E; Hewitt R; Liedtke M
Immunotherapy; 2019 Jun; 11(9):801-811. PubMed ID: 31094254
[TBL] [Abstract][Full Text] [Related]
57. Multiple myeloma: present and future.
Hussein MA; Juturi JV; Lieberman I
Curr Opin Oncol; 2002 Jan; 14(1):31-5. PubMed ID: 11790977
[TBL] [Abstract][Full Text] [Related]
58. [Immune defects in multiple myeloma].
Shindo T; Kimura S
Nihon Rinsho; 2015 Jan; 73(1):52-6. PubMed ID: 25626304
[TBL] [Abstract][Full Text] [Related]
59. Optimal use of bisphosphonates in patients with multiple myeloma.
Terpos E; Roodman GD; Dimopoulos MA
Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
[No Abstract] [Full Text] [Related]
60. Update on proteasome inhibitors in multiple myeloma.
Richardson PG
Clin Adv Hematol Oncol; 2014 Mar; 12(3):179-81. PubMed ID: 24927266
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
